External Site Lead - Global External Manufacturing

City Therapeutics raises $200M for RNAi beyond the liver. City Therapeutics' $200 million IPO backs RNAi development beyond the liver, with an anticoagulant contender and partnerships in eye and brain diseases. Key facts. * IPO proceeds: City Therapeutics raised $200 million in an upsized initial public offering. * Lead therapy: An RNA interference candidate could become an alternative to blockbuster-selling anticoagulants. * Eye-disease partnership: City Therapeutics has a partnership with Bausch + Lomb in eye diseases. * Central nervous system partnership: City Therapeutics has a partnership with Biogen in central nervous system disorders. City Therapeutics raised $200 million in an upsized initial public offering to advance RNA interference medicines, including a platform aimed at reaching tissues beyond the liver. City Therapeutics has raised $200 million in an upsized initial public offering, securing capital for a drug-development strategy that reaches beyond the liver, an important destination for RNA interference medicines. Its investment case combines a lead therapy that could offer an alternative to established anticoagulants with technology intended to deliver gene-silencing drugs to other tissues. The financing addresses a central challenge in biotechnology: turning a promising way of intervening in disease into medicines that can reach the right cells safely and reliably. City also has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. Those relationships give the platform a broader development footprint, but they do not establish that its experimental treatments will work. More capital, but no shortcut to clinical evidence. The upsized offering raised $200 million, according to MedCity News. The financing gives City resources to pursue its pipeline and delivery technology. It does not, on its own, resolve the scientific and clinical risks that will determine their value. The distinction matters because an IPO measures a company's ability to secure funding, not the effectiveness of its medicines. A larger offering can support development work, but investors still need evidence that a treatment produces its intended biological effect and that the effect translates into a benefit for patients. The supplied offering details do not establish a share price, valuation, net proceeds after expenses or a program-by-program spending plan. Without those terms, the amount raised cannot support a precise judgment about dilution, cash runway or how much capital will reach any particular therapy. The sounder focus is what evidence the financing may help City generate. Why delivery beyond the liver matters. RNA interference, or RNAi, is a way to reduce production of a selected protein by targeting the molecular instructions used to make it. Rather than directly blocking a protein after it has been produced, an RNAi medicine seeks to interrupt the process upstream. Its therapeutic usefulness depends on choosing a suitable target and delivering the treatment to the cells that matter. Delivery is therefore part of the medicine's core design, not merely a packaging problem. A treatment must reach the relevant tissue, enter the appropriate cells and remain active long enough to produce a useful effect. Success at silencing a target in one setting does not automatically establish that the same approach will succeed elsewhere in the body. For City, expansion beyond the liver could widen the range of diseases its technology can address. But that opportunity also sets a demanding standard of proof. Investors will need to distinguish evidence that a drug reaches a tissue from evidence that it changes the course of disease. Both are important, and neither should be assumed from the platform's ambition. The anticoagulant opportunity rests on patient benefit. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That places the program against an established treatment category rather than a market with no existing options. The commercial opportunity is meaningful in principle, but the description of a potential alternative is not evidence of superiority. City's lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. Anticoagulants reduce the blood's ability to form clots. Their clinical use involves balancing protection against harmful clotting with the risk of bleeding. Any new approach seeking a role in that treatment landscape must demonstrate a useful balance of benefit and risk in the patients for whom it is intended. For an RNAi candidate, the connection between gene silencing and patient outcomes will be central. Showing that a target has been suppressed is different from showing that patients experience fewer harmful events or an acceptable safety profile. Duration of action and the ability to manage treatment around changing medical needs would also be relevant questions, rather than advantages investors should presume. The available facts do not identify the lead therapy's target, trial stage, dosing schedule or clinical results. They therefore support an opportunity to investigate, not a forecast that City will displace existing medicines. Partnerships broaden the platform's reach. The Bausch + Lomb and Biogen partnerships extend City's work into eye diseases and central nervous system disorders, respectively. They provide concrete examples of how the company's RNAi design and delivery technology is being pursued outside its lead program. These relationships matter because a platform business depends on more than the prospects of an individual drug. If technology can support useful medicines across distinct tissues and diseases, it may create additional development opportunities. Conversely, a result in one program may say little about another when the target cells, delivery requirements and disease biology differ. The partnerships should not be treated as interchangeable proof points. Work in eye disease cannot by itself validate a treatment for a central nervous system disorder, and neither establishes the clinical prospects of the anticoagulant alternative. No partnership payments, milestone amounts or royalty terms are supplied. Investors consequently cannot use these relationships to calculate a dependable stream of future cash. Their demonstrated significance here is the breadth of the development relationships, not a quantifiable contribution to revenue. What investors should watch after the IPO. The next useful disclosures would connect City's financing to a clear development plan: which programs it intends to prioritize, what studies are designed to establish and how spending is divided between individual candidates and the delivery platform. Those details would help investors judge whether the company is pursuing a focused set of testable objectives. For the lead therapy, attention should fall on clinical evidence relevant to anticoagulant use, rather than molecular activity alone. For the broader platform, the important question is whether delivery outside the liver can produce reproducible, therapeutically useful results without unacceptable safety costs. City's $200 million IPO provides capital to pursue those questions. Its partnerships broaden the scope of the effort, while the lead program gives investors a specific potential commercial application to assess. The financing is a consequential step, but the investment case ultimately depends on what the company can demonstrate with that capital - not simply how much it raised. Frequently asked questions. How much did City Therapeutics raise in its IPO? City Therapeutics raised $200 million in an upsized initial public offering. The financing supports a company developing RNA interference medicines and technology intended to reach tissues beyond the liver. The available facts do not specify the offering's share price, valuation, net proceeds after expenses or allocation of funding among programs. What is RNA interference? RNA interference, or RNAi, reduces production of a selected protein by targeting the molecular instructions used to make it. For a treatment to work, it must reach the appropriate cells and produce a useful biological effect. Successful target suppression must then translate into meaningful patient benefit with an acceptable safety profile. Why is City Therapeutics pursuing RNAi beyond the liver? Reaching tissues beyond the liver could allow City Therapeutics to pursue a broader range of diseases. Delivery is a central challenge because an RNAi medicine must enter the relevant cells to act. Evidence of delivery is important, but it does not by itself establish that a treatment improves patient outcomes. What is the opportunity for City's lead therapy? City Therapeutics' lead RNAi therapy could become an alternative to blockbuster-selling anticoagulants. That creates a potential opportunity in an established treatment category, but does not demonstrate an advantage over existing medicines. The supplied facts do not identify the candidate's target, clinical stage, dosing schedule or results. Which companies have partnerships with City Therapeutics? City Therapeutics has partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. These relationships broaden the applications being pursued with its technology. They do not establish clinical success, and the supplied facts contain no payments, milestones or royalty terms from which to estimate future revenue. What should investors watch following the IPO? Investors should watch for program priorities, spending plans and evidence connecting RNAi activity to patient benefit. For the lead therapy, efficacy and safety relevant to anticoagulant use will matter. For the broader platform, the central question is whether delivery beyond the liver produces reproducible, therapeutically useful results.

Arrowhead's blood-brain barrier tech is 'arguably better' than others, analysts say after data drop. October 15, 2026 | Arrowhead Pharmaceuticals' siRNA candidate achieved "compelling" tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperform other blood-brain barrier platforms, according to Stifel. Arrowhead Pharmaceuticals' investigational gene silencer lowered tau protein levels in an early study, suggesting that the biotech's approach to bypass the blood-brain barrier may be better than competing technologies. The findings "provide important clinical validation" for Arrowhead's platform for targeting the central nervous system through subcutaneously administered drugs, Stifel analysts said in a Wednesday note. Results from the Phase 1/2a study, disclosed Wednesday, showed a 40% average reduction in CSF tau at day 105 in healthy volunteers who were treated with the low 2.1-mg/kg dose of the siRNA candidate, called ARO-MAPT, on days 1, 8 and 15. In those given a 6.4-mg/kg dose on the same days, CSF tau dropped by 69% on average at day 105. Meanwhile, a 12.8-mg/kg dose of ARO-MAPT injected on days 1 and 15 triggered a mean CSF tau reduction of 73% at day 105. The maximum CSF tau reduction reached 85% in the high-dose cohort. The early trial is actively enrolling patients, with a target of 112 participants, including healthy volunteers for the study's first part and patients with early Alzheimer's disease for the second portion. Wednesday's data came from healthy volunteers. As for safety, the primary objective of the Phase 1/2a trial, Arrowhead said that ARO-MAPT was "generally well tolerated." Treatment-emergent adverse events were largely mild, with no serious side effects, deaths or dropouts due to toxicities. The data, while early, could set Arrowhead up to compete against Biogen, analysts say. Both companies are advancing tau-targeting therapies that work by suppressing the expression of the MAPT gene, which codes for the tau protein. "While details are still relatively light, the data looking compelling," Stifel told investors in a note on Wednesday, adding that the interim findings are "arguably better than what we've seen with other BBB platforms." The firm also hinted at a potential competitive edge for Arrowhead's subcutaneous siRNA asset, writing that the CSF tau knockdown "looks better than [Biogen's] BIIB080," an anti-tau antisense oligonucleotide also known as diranersen that is injected directly into the spine. ARO-MAPT, meanwhile, can be delivered via an injection under the skin. Phase 1b data for diranersen published in 2023 showed that, across various dose levels, CSF tau declined by an average of 30% to 49% at eight weeks after the final dose of Biogen's asset. Diranersen's tau-lowering effect persisted through 24 weeks after the last dose, hitting an average tau reduction of up to 56%. The trial enrolled 46 patients with mild Alzheimer's disease, and its primary endpoint was safety; CSF tau was set as a key exploratory outcome. There have been no direct head-to-head studies between ARO-MAPT and diranersen, which prompted Jefferies to be a bit more reserved about comparing the two assets. The firm in a Wednesday note pointed to differences in study populations and dose strengths. In May, Biogen announced that diranersen failed to meet its primary goal of showing a dose-response effect in cognitive and functional outcomes in the Phase 2 CELIA study. Nevertheless, the company detected "robust reductions in tau pathology" that were consistent with the Phase 1b study. Biogen also touted cognitive improvements and slowing of decline, especially in patients who received the lowest dose of diranersen. Based on these efficacy signals, Biogen has decided to push diranersen into registrational development, though the company has yet to specify a timeline for this. Arrowhead is also moving forward with ARO-MAPT, with additional healthy volunteer and Alzheimer's disease data expected next year. Arrowhead is also in talks with health regulators to enable studies in MAPT-associated frontotemporal dementia and progressive supranuclear palsy, according to the Wednesday announcement.

citybiz+ Altay Therapeutics raises $37M to advance muscular dystrophy drug. October 15, 2026 San Francisco-based Altay Therapeutics raised $37 million in Series A financing co-led by Sound Bioventures and HealthCap to advance its oral muscular dystrophy drug, DX5057. The candidate targets DUX4, a transcription factor associated with facioscapulohumeral muscular dystrophy (FSHD). Funds will support Phase 1 and Phase 2 proof-of-concept trials, with clinical development expected to begin in early 2027. DX5057 has received FDA orphan drug designation. Altay Therapeutics CEO James Breitmeyer. San Francisco-based Altay Therapeutics has raised $37 million in Series A financing co-led by Sweden's Sound Bioventures, which has U.S. offices in Bethesda, Md., and HealthCap, with participation from new investors including Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, and Global BioAccess Fund. The company seeks to advance an experimental oral drug for facioscapulohumeral muscular dystrophy (FSHD), with plans to use the proceeds to advance its lead candidate, DX5057, through Phase 1 and Phase 2 proof-of-concept clinical trials. Clinical development is expected to begin in the first quarter of 2027. FSHD is an inherited muscular dystrophy that often affects the face, shoulders and upper arms before progressing to the trunk and lower extremities. The company is targeting DUX4, a gene whose abnormal activity in skeletal muscle triggers muscle damage and degeneration, as Altay believes an oral small-molecule treatment could offer a practical option for long-term therapy. DX5057 is designed to bind DUX4 and inhibit its activity, reducing the expression of downstream genes associated with muscle injury. The candidate is intended to intervene in a disease-linked biological mechanism, allowing systemic distribution across affected muscles, an important consideration for a disorder that can involve multiple muscle groups throughout the body. "There are no disease-modifying therapies approved for FSHD, and the patient community is in need of a durable, practical solution. DX5057 is an oral medicine that acts systemically to shut down DUX4 at its source," said James Breitmeyer, M.D., Ph.D., CEO of Altay. Breitmeyer, an oncologist and pharmaceutical executive, serves on the board of Vaxart, a biotechnology company developing oral vaccines. Before joining Altay, Breitmeyer founded and led Oncternal Therapeutics as president and CEO from 2016 to 2025, overseeing the development of its oncology pipeline. His previous leadership roles include president of Bavarian Nordic's U.S. operations, executive vice president and chief medical officer at Cadence Pharmaceuticals, and vice president of biotechnology at Eli Lilly and Co. Earlier in his career, he held clinical development positions at Serono Laboratories, Applied Molecular Evolution and Zogenix, and served on the clinical and teaching faculties of Dana-Farber Cancer Institute and Harvard Medical School. Altay reported that nonclinical studies, including research using a transgenic mouse model expressing human DUX4, showed reductions in DUX4-associated activity, downstream gene expression, and markers of muscle injury, alongside preservation of disease-relevant muscle function. The candidate has received orphan drug designation from the U.S. Food and Drug Administration.